Redeye raises its estimates and valuation for BONESUPPORT considerably following discussions with management and a review of the company’s sales prospects. With solid fundamentals and a strong balance sheet, we anticipate impressive long-term market up-take in the US, bringing the company to an entirely new level. We see further upside with clear catalysts around the corner to help the stock continue to outperform.